Search Results - "Burkholder, Tiana"

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma by Wick, Antje, Desjardins, Annick, Suarez, Cristina, Forsyth, Peter, Gueorguieva, Ivelina, Burkholder, Tiana, Cleverly, Ann Louise, Estrem, Shawn T., Wang, Shuaicheng, Lahn, Michael M., Guba, Susan C., Capper, David, Rodon, Jordi

“…Summary Purpose Galunisertib, a TGF-β inhibitor, has demonstrated antitumor effects in preclinical and radiographic responses in some patients with malignant…”
Get full text

Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer by Gordon, Alan N, Teneriello, Michael, Janicek, Mike F, Hines, Jeffrey, Lim, Peter C, Chen, M. Dwight, Vaccarello, Luis, Homesley, Howard D, McMeekin, Scott, Burkholder, Tiana L, Wang, Yanping, Zhao, Luping, Orlando, Mauro, Obasaju, Coleman K, Gill, John F, Tai, Datchen F

“…Abstract Objective The safety and efficacy of gemcitabine plus carboplatin (GC) or paclitaxel plus carboplatin (TC) induction regimens with or without…”
Get full text

Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with chemoradiotherapy in newly diagnosed malignant gliomas by Suarez, Cristina, Rodon, Jordi, Desjardins, Annick, Forsyth, Peter A. J., Gueorguieva, Ivelina, Cleverly, Ann, Burkholder, Tiana, Desaiah, Durisala, Lahn, Michael M. F., Wick, Wolfgang

“…Abstract only 2039 Background: Based on preclinical data suggesting an additive antitumor effect of combining TGF-ß inhibitors with temozolomide based…”
Get full text

ACTR-16. PHASE 2 STUDY EVALUATING SAFETY, PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EFFICACY OF THE ORAL TRANSFORMING GROWTH FACTOR-BETA (TGF-β) RECEPTOR I KINASE INHIBITOR GALUNISERTIB WHEN COMBINED WITH CHEMORADIOTHERAPY IN NEWLY DIAGNOSED MALIGNANT GLIOMA by Desjardins, Annick, Suarez, Cristina, Forsyth, Peter, Gueorguieva, Ivelina, Cleverly, Ann, Burkholder, Tiana, Desaiah, Durisala, Lahn, Michael M, Guba, Susan C, Wick, Wolfgang, Rodon, Jordi

Get full text

Phase III Trial of Induction Gemcitabine or Paclitaxel Plus Carboplatin Followed by Elective Paclitaxel Consolidation in Ovarian Cancer: Interim Analysis of Induction Chemotherapy by Gordon, Alan N, Teneriello, Michael, Lim, Peter, Janicek, Mike F, Burkholder, Tiana L, Wang, Yanping, Orlando, Mauro, Obasaju, Coleman K, Gill, John F, Tai, Datchen F

“…Abstract Background Combination paclitaxel and carboplatin (TC) is the standard of care for first-line (induction) treatment of ovarian cancer. Gemcitabine…”
Get full text

Phase III Trial of Induction Gemcitabine or Paclitaxel Plus Carboplatin Followed by Elective Paclitaxel Consolidation in Ovarian Cancer: Interim Analysis of Induction Chemotherapy by Gordon, Alan N, Teneriello, Michael, Lim, Peter, Janicek, Mike F, Burkholder, Tiana L, Wang, Yanping, Orlando, Mauro, Obasaju, Coleman K, Gill, John F, Tai, Datchen F

“…Abstract Background Combination paclitaxel and carboplatin (TC) is the standard of care for first-line (induction) treatment of ovarian cancer. Gemcitabine…”
Get full text